Role of ABRACL in the occurrence and development of malignant tumors

doi:10.3760/cma.j.cn371439-20230506-00104

Abstract

Abstract:

The ABRACL protein， the regulator of actin and cell motility， belongs to the HSPC280 family， and its conserved hydrophobic groove can interact with other proteins to facilitate actin motility and cellular activity. ABRACL is upregulated in tumor tissues and is closely linked with the proliferation and migration of tumor cells. A deeper understanding of the role of ABRACL in tumorigenesis and development may provide new ideas and insights for ABRACL to prevent or reverse tumor progression.

Key words: Neoplasms, Carcinogenesis, Cytoskeleton, ABRACL

Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui. Role of ABRACL in the occurrence and development of malignant tumors[J]. Journal of International Oncology, 2023, 50(9): 544-547.

References 27

[1]	Bakir B, Chiarella AM, Pitarresi JR, et al. EMT, MET, plasticity, and tumor metastasis[J]. Trends Cell Biol, 2020, 30(10): 764-776. DOI: 10.1016/j.tcb.2020.07.003. pmid: 32800658
[2]	Fares J, Fares MY, Khachfe HH, et al. Molecular principles of metastasis: a hallmark of cancer revisited[J]. Signal Transduct Target Ther, 2020, 5(1): 28. DOI: 10.1038/s41392-020-0134-x.
[3]	Hyrskyluoto A, Vartiainen MK. Regulation of nuclear actin dynamics in development and disease[J]. Curr Opin Cell Biol, 2020, 64: 18-24. DOI: 10.1016/j.ceb.2020.01.012. pmid: 32088545
[4]	Li J, Chen H. Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells[J]. Bioengineered, 2022, 13(4): 9019-9031. DOI: 10.1080/21655979.2022.2056821. pmid: 35341461
[5]	Lin J, Zhou T, Wang J. Solution structure of the human HSPC280 protein[J]. Protein Sci, 2011, 20(1): 216-223. DOI: 10.1002/pro.548. pmid: 21082705
[6]	Pang TL, Chen FC, Weng YL, et al. Costars, a dictyostelium protein similar to the C-terminal domain of STARS, regulates the actin cytoskeleton and motility[J]. J Cell Sci, 2010, 123(Pt 21): 3745-3755. DOI: 10.1242/jcs.064709.
[7]	Hsiao BY, Chen CH, Chi HY, et al. Human costars family protein ABRACL modulates actin dynamics and cell migration and associates with tumorigenic growth[J]. Int J Mol Sci, 2021, 22(4): 2037. DOI: 10.3390/ijms22042037.
[8]	Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis[J]. Nat Rev Cancer, 2018, 18(9): 533-548. DOI: 10.1038/s41568-018-0038-z. pmid: 30002479
[9]	Novikov NM, Zolotaryova SY, Gautreau AM, et al. Mutational drivers of cancer cell migration and invasion[J]. Br J Cancer, 2021, 124(1): 102-114. DOI: 10.1038/s41416-020-01149-0.
[10]	Ghouzlani A, Kandoussi S, Tall M, et al. Immune checkpoint inhibitors in human glioma microenvironment[J]. Front Immunol, 2021, 12: 679425. DOI: 10.3389/fimmu.2021.679425.
[11]	Youssef G, Miller JJ. Lower grade gliomas[J]. Curr Neurol Neurosci Rep, 2020, 20(7): 21. DOI: 10.1007/s11910-020-01040-8.
[12]	Liu B, Guan Y, Wang M, et al. ABRACL as a potential prognostic biomarker and correlates with immune infiltration in low-grade gliomas[J]. Interdiscip Neurosurg, 2022, 30: 101618. DOI: 10.1016/j.inat.2022.101618.
[13]	Brägelmann J, Lorenz C, Borchmann S, et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG -Ⅰ[J]. Nat Commun, 2021, 12(1): 5505. DOI: 10.1038/s41467-021-25728-8. pmid: 34535668
[14]	Ben-Dror J, Shalamov M, Sonnenblick A. The history of early breast cancer treatment[J]. Genes (Basel), 2022, 13(6): 960. DOI: 10.3390/genes13060960.
[15]	Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226. DOI: 10.1016/j.tcb.2018.12.001. pmid: 30594349
[16]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
[17]	曹莎莎, 段丽娟, 周福有. 基于TCGA分析ABRACL在食管癌组织中的表达及机制[J]. 河南医学研究, 2021, 30(34): 6340-6344. DOI: 10.3969/j.issn.1004-437X.2021.34.002.
[18]	Wang D, Liu H, Ren C, et al. High expression of ABRACL is associated with tumorigenesis and affects clinical outcome in gastric cancer[J]. Genet Test Mol Biomarkers, 2019, 23(2): 91-97. DOI: 10.1089/gtmb.2018.0195.
[19]	Fan S, Chen P, Li S. miR-145-5p inhibits the proliferation, migration, and invasion of esophageal carcinoma cells by targeting ABRACL[J]. Biomed Res Int, 2021, 2021: 6692544. DOI: 10.1155/2021/6692544.
[20]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[21]	Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279. DOI: 10.3322/caac.21657.
[22]	Zhao Y, Li S, Childs EE, et al. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-α-induced liver injury[J]. J Biol Chem, 2001, 276(29): 27432-27440. DOI: 10.1074/jbc.M102465200. pmid: 11369777
[23]	Ura B, Monasta L, Arrigoni G, et al. A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate[J]. Oncotarget, 2017, 8(65): 109536-109545. DOI: 10.18632/oncotarget.22725.
[24]	Deutsch EW, Omenn GS, Sun Z, et al. Advances and utility of the human plasma proteome[J]. J Proteome Res, 2021, 20(12): 5241-5263. DOI: 10.1021/acs.jproteome.1c00657. pmid: 34672606
[25]	Saghaleyni R, Sheikh Muhammad A, Bangalore P, et al. Machine learning-based investigation of the cancer protein secretory pathway[J]. PLoS Comput Biol, 2021, 17(4): e1008898. DOI: 10.1371/journal.pcbi.1008898.
[26]	Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colo-rectal cancer[J]. Int J Mol Sci, 2022, 23(2): 852. DOI: 10.3390/ijms23020852.
[27]	Battaglia RA, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration[J]. F1000Res, 2018, 7: F1000 Faculty Rev-1796. DOI: 10.12688/f1000research.15967.1.